CHESHIRE — Forbes Magazine named Alexion Pharmaceuticals the world’s second-most innovative company in its current issue.
This is the second year in a row the company, based at 352 Knotter Drive, has won the distinction.
“We’re certainly gratified to see we’re number 2 in the rankings again this year,” said company spokesman Irving Adler. “Innovative care has been the company’s life since it was founded in 1992.”
The company creates medications for rare and ultra-rare diseases. A rare disease is one that affects less than 500 people out of a million. An ultra-rare disease is defined as one that affects less than 20 out of a million people.
It’s most well-known drug, Solaris, treats patients with a progressive and life threatening disease that kills red blood cells. It is also used to treat a genetic disease that can progressively damage vital organs, leading to stroke, heart attack, kidney failure and death.
Solaris was 15 years in development and first approved by the FDA in 2007.
The company, which now has 400 employees in two separate buildings in Cheshire, will be moving to New Haven in 2015 because it has outgrown its current locations, Adler said.
“We’re expanding to serve more people and be under one roof,” he said.
Cheshire Economic Development Director, Jerry Sitko, said it was no surprise to him that the company earned the distinction again.
“They’re a first rate, extremely well run company,” Sitko said. “It’s good news for us and it’s good news for the town.”